Ligation of CM1 enhances apoptosis of lung cancer cells through different mechanisms in conformity with EGFR mutation

Although remarkable developments in lung cancer treatments have been made, lung cancer remains the leading cause of cancer mortality worldwide. Epidermal growth factor receptor (EGFR) is occasionally mutated in non-small cell lung cancer and heterogeneity in treatment response results from different EGFR mutations. In the present study, we found that centrocyte/centroblast marker 1 (CM1), previously reported as a possible apoptosis inducer of B lymphoma cells, is expressed on both A549 with wild-type EGFR and HCC827 with mutant EGFR lung cancer cells. Ligation of CM1 with anti-CM1 mAb enhanced apoptosis in both lung cancer cell lines through generation of reactive oxygen species (ROS) and disruption of mitochondrial membrane potential, however, the signaling mechanisms differed from each other. Further studies to investigate the signaling mechanisms identified that ligation of CM1-induced apoptosis in A549 cell involved FasL expression, caspase-8, ERK1/2 and Akt kinase, whereas apoptosis of HCC827 cells was induced through caspase-9, JNK and c-jun-dependent pathways. Taken together, we suggest that CM1 could be developed as a therapeutic target of lung cancer regardless of EGFR mutation status.

[1]  H. Hieronymus,et al.  FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR , 2011, Nature.

[2]  Long-Sen Chang,et al.  Piceatannol induces Fas and FasL up-regulation in human leukemia U937 cells via Ca2+/p38alpha MAPK-mediated activation of c-Jun and ATF-2 pathways. , 2010, The international journal of biochemistry & cell biology.

[3]  Shu-guang Wang,et al.  The Role of MAPK-ERK Pathway in 67-kDa Laminin Receptor-Induced FasL Expression in Human Cholangiocarcinoma Cells , 2010, Digestive Diseases and Sciences.

[4]  K. Nishio,et al.  Mitogen‐activated protein kinase phosphatase‐1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor‐tyrosine kinase , 2009, The FEBS journal.

[5]  Susanna M Cramb,et al.  The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  S. Wacholder,et al.  Environment And Genetics in Lung cancer Etiology (EAGLE) study: An integrative population-based case-control study of lung cancer , 2008, BMC public health.

[7]  D. Hicklin,et al.  Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non–small cell lung cancers , 2007, Molecular Cancer Therapeutics.

[8]  D. Camidge The potential of death receptor 4- and 5-directed therapies in the treatment of lung cancer. , 2007, Clinical lung cancer.

[9]  G. Park,et al.  Ligation of centrocyte/centroblast marker 1 on Epstein-Barr virus--transformed B lymphocytes induces cell death in a reactive oxygen species--dependent manner. , 2006, Human immunology.

[10]  G. Giaccone,et al.  Cell Death Independent of Caspases: A Review , 2005, Clinical Cancer Research.

[11]  A. A. Starkov,et al.  Mitochondrial metabolism of reactive oxygen species , 2005, Biochemistry (Moscow).

[12]  Michael Peyton,et al.  Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. , 2005, Cancer research.

[13]  P. Vandenabeele,et al.  Activation of p38 MAPK is required for Bax translocation to mitochondria, cytochrome c release and apoptosis induced by UVB irradiation in human keratinocytes , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  N. Moldovan,et al.  Oxygen free radicals and redox biology of organelles , 2004, Histochemistry and Cell Biology.

[15]  R. Alexander,et al.  Reactive oxygen species as mediators of angiogenesis signaling. Role of NAD(P)H oxidase , 2004, Molecular and Cellular Biochemistry.

[16]  Keith M. Kerr,et al.  Gene Expression Profiling in Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[17]  Jorge A. Almenara,et al.  Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process , 2004, Oncogene.

[18]  K. Reddy,et al.  Role of MAP kinase in tumor progression and invasion , 2003, Cancer and Metastasis Reviews.

[19]  H. Hansen Treatment of advanced non-small cell lung cancer , 2002, BMJ : British Medical Journal.

[20]  S. Terrazzino,et al.  H2O2 induces upregulation of Fas and Fas ligand expression in NGF‐differentiated PC12 cells: Modulation by cAMP , 2002, Journal of neuroscience research.

[21]  YeongSeok Kim,et al.  CM1 ligation initiates apoptosis in a caspase 8-dependent manner in Ramos cells and in a mitochondria-controlled manner in Raji cells. , 2002, Human immunology.

[22]  M. Campiglio,et al.  Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  John Mendelsohn,et al.  The EGF receptor family as targets for cancer therapy , 2000, Oncogene.

[24]  D. Hur,et al.  CM1, a possible novel activation molecule on human lymphocytes. , 2000, Immunology letters.

[25]  M. Macey,et al.  Subcellular distribution and redistribution of Bcl-2 family proteins in human leukemia cells undergoing apoptosis. , 1999, Blood.

[26]  C. Borner,et al.  Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c , 1998, Nature.

[27]  M. V. Heiden,et al.  Bcl-xL Regulates the Membrane Potential and Volume Homeostasis of Mitochondria , 1997, Cell.

[28]  Dean P. Jones,et al.  Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.

[29]  S. Korsmeyer,et al.  Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell death , 1995, Cell.

[30]  Matthews Ji,et al.  Lung cancer. An update. , 1985 .

[31]  Barry H. Smith,et al.  A continuous tumor‐cell line from a human lung carcinoma with properties of type II alveolar epithelial cells , 1976, International journal of cancer.

[32]  Sun-Mi Park,et al.  CD95 promotes tumour growth , 2011, Nature.

[33]  P. Jänne,et al.  Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. , 2005, Journal of the National Cancer Institute.

[34]  I. Klyubin,et al.  Roles of reactive oxygen species: signaling and regulation of cellular functions. , 1999, International review of cytology.